An autonomous activation of interleukin-17 receptor signaling sustains inflammation and promotes disease progression
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Anti-interleukin-17 (IL-17) therapy has been used in various autoimmune diseases. However, the efficacy is unexpectedly limited in several IL-17-associated diseases, and the mechanism of limited efficacy remains unclear. Here, we show that a molecular complex containing the adaptor molecule Act1 and tyrosine phosphatase SHP2 mediated autonomous IL-17R signaling that accelerated and sustained inflammation. SHP2, aberrantly augmented in various autoimmune diseases, was induced by IL-17A itself in astrocytes and keratinocytes, sustaining chemokine production even upon anti-IL-17 therapies. Mechanistically, SHP2 directly interacted with and dephosphorylated Act1, which replaced Act1-TRAF5 complexes and induced IL-17-independent activation of IL-17R signaling. Genetic or pharmacologic inactivation of SHP2, or blocking Act1-SHP2 interaction, paralyzed both IL-17-induced and IL-17-independent signaling and attenuated primary or relapsing experimental autoimmune encephalomyelitis. Therefore, Act1-SHP2 complexes mediate an alternative pathway for autonomous activation of IL-17R signaling, targeting which could be a therapeutic option for IL-17-related diseases in addition to current antibody therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261
Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301668 · Cited by 1,547
The ‘Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling
Neel, B. G., Gu, H., & Pao, L. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00091-4 · Cited by 1,249
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Chen, Y.-N. P., LaMarche, M. J., Chan, H. M., Fekkes, P., Garcia-Fortanet, J., Acker, M. G., Antonakos, B., Chen, C. H.-T., Chen, Z., Cooke, V. G., et al. (2016) · Nature · doi:10.1038/nature18621 · Cited by 925
Neuronal vulnerability and multilineage diversity in multiple sclerosis
Schirmer, L., Velmeshev, D., Holmqvist, S., Kaufmann, M., Werneburg, S., Jung, D., Vistnes, S., Stockley, J. H., Young, A., Steindel, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1404-z · Cited by 638
Qian, Y., Liu, C., Hartupee, J., Altuntas, C. Z., Gulen, M. F., Jane-wit, D., Xiao, J., Lu, Y., Giltiay, N., Liu, J., et al. (2007) · Nature Immunology · doi:10.1038/ni1439 · Cited by 614
Targan, S. R., Feagan, B., Vermeire, S., Panaccione, R., Melmed, G. Y., Landers, C., Li, D., Russell, C., Newmark, R., Zhang, N., et al. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.298 · Cited by 383
Kang, Z., Altuntas, C. Z., Gulen, M. F., Liu, C., Giltiay, N., Qin, H., Liu, L., Qian, W., Ransohoff, R. M., Bergmann, C., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.03.004 · Cited by 297
Act1 mediates IL-17-induced EAE pathogenesis selectively in NG2+ glial cells
Kang, Z., Wang, C., Zepp, J., Wu, L., Sun, K., Zhao, J., Chandrasekharan, U., DiCorleto, P. E., Trapp, B. D., Ransohoff, R. M., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3505 · Cited by 218
Bulek, K., Liu, C., Swaidani, S., Wang, L., Page, R. C., Gulen, M. F., Herjan, T., Abbadi, A., Qian, W., Sun, D., et al. (2011) · Nature Immunology · doi:10.1038/ni.2080 · Cited by 192
Cited by
Th17 cell pathogenicity in autoimmune disease
Park, E., & Ciofani, M. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01535-9 · Cited by 75
“By contrast, anti-IL-17A therapy has shown no or limited clinical bene fi ts in other autoimmune diseases such as MS or RA 248 , and one possible explanation is SHP2-mediated IL-17-independent IL-17R signaling that nulli fi es the blockade of IL-17A 249 .”
Targeting interleukin-17 as a novel treatment option for fibrotic diseases
Sisto, M., & Lisi, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010164 · Cited by 22
Structural basis for ACT1 oligomerization induced by IL-17 receptor hetero-tetramer
Zhang, H., Bai, X.-C., & Zhang, X. (2025) · Nature Communications · doi:10.1038/s41467-025-67536-4 · Cited by 4
Metadata
- Authors
- Luo, Q., Liu, Y., Shi, K., Shen, X., Yang, Y., Liang, X., Lu, L., Qiao, W., Chen, A., Hong, D., Sun, Y., & Xu, Q.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2023-09
- Volume
- 56
- Issue
- 9
- Pages
- 2006-2020.e6
- ISSN
- 1074-7613 (ISSN-L)
- OpenAlex
- W4384830601
- Cited by
- 70
- References
- 12
- FWCI
- 7.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An autonomous activation of interleukin-17 receptor signaling sustains inflammation and promotes disease progression. https://app.cochat.ai/papers/10.1016/j.immuni.2023.06.012
- The paper
- Luo, Q., Liu, Y., Shi, K., Shen, X., Yang, Y., Liang, X., Lu, L., Qiao, W., Chen, A., Hong, D., Sun, Y., & Xu, Q. (2023). An autonomous activation of interleukin-17 receptor signaling sustains inflammation and promotes disease progression. Immunity. https://doi.org/10.1016/j.immuni.2023.06.012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.